Cancer Family
Secondary Neoplasm
CI-CAN-00000050Explore in graph →
Non-malignant4,276 active trials56 approved drugs532 evidence items
- NCIt
- C36255
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000050Explore in graph →
Clinical trials
14,673 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03907852 | Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer | active not recruiting | Phase 1 / Phase 2 | 57 | TCR2 TherapeuticsINDUSTRY | 2 | Aug 27, 2025 | clinicaltrials |
| NCT06989671 | SYS6002 Plus JMT101 and Enlonstobart Injection in Participants With HNSCC | not yet recruiting | Phase 2 | 430 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 0 | Aug 27, 2025 | clinicaltrials |
| NCT07018661 | [18F]F-FAPI PET/CT and Laparoscopy in Staging Advanced Gastric Cancer(PLASTIC-3) | recruiting | Phase 2 / Phase 3 | 250 | Leiden University Medical CenterOTHER | 1 | Aug 27, 2025 | clinicaltrials |
| NCT05796089 | Chemotherapy and Immunotherapy in Extensive-Stage Small-Cell Lung Cancer With Thoracic Radiotherapy(CHEST RT) | active not recruiting | Phase 2 | 35 | Trans Tasman Radiation Oncology GroupOTHER | 1 | Aug 26, 2025 | clinicaltrials |
| NCT07141186 | QL1706 in Patients With Recurrent and Metastatic Cervical Cancer Resistant to Prior PD-1/PD-L1 Antibody Therapy | not yet recruiting | Phase 2 | 50 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Aug 26, 2025 | clinicaltrials |
| NCT07141771 | An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing | not yet recruiting | Phase 1 / Phase 2 | 100 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Aug 26, 2025 | clinicaltrials |
| NCT07142421 | A Study of Trifluridine/Tipiracil Combined With Anlotinib as Second-line Treatment for Recurrent and Metastatic Esophageal Squamous Cell Carcinoma | active not recruiting | Phase 2 | 35 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Aug 26, 2025 | clinicaltrials |
| NCT06127238 | Study of ST-1898 in Advanced Renal Cell Carcinoma | active not recruiting | Phase 1 / Phase 2 | 90 | Beijing Scitech-Mq Pharmaceuticals LimitedINDUSTRY | 1 | Aug 24, 2025 | clinicaltrials |
| NCT06359847 | Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer | recruiting | Phase 2 | 60 | Beijing Scitech-Mq Pharmaceuticals LimitedINDUSTRY | 1 | Aug 24, 2025 | clinicaltrials |
| NCT06683846 | Ivonescimab in the Treatment of Multiple Advanced Tumors | recruiting | Phase 2 | 400 | Fudan UniversityOTHER | 1 | Aug 24, 2025 | clinicaltrials |
| NCT07139470 | Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer | not yet recruiting | Phase 1 / Phase 2 | 59 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 24, 2025 | clinicaltrials |
| NCT07135804 | Iparomlimab and Tuvonralimab Injection for Untreated Locally Advanced Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 45 | Second Affiliated Hospital of Nanchang UniversityOTHER | 0 | Aug 22, 2025 | clinicaltrials |
| NCT07137858 | Adebrelimab Combined With Carboplatin and Albumin-bound Taxanol in the Treatment of Resectable Locally Advanced Oral Squamous Cell Carcinoma Cardiac, Randomized, Phase II Exploratory Study | not yet recruiting | Phase 2 | 70 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Aug 22, 2025 | clinicaltrials |
| NCT05113368 | Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer | recruiting | Phase 2 | 31 | Sarah K. Lynam MDOTHER | 1 | Aug 21, 2025 | clinicaltrials |
| NCT05446467 | Pembrolizumab in Combination With Low-dose PFas Neoadjuvant Treatment for Locally Advanced HNSCC | recruiting | Phase 2 | 80 | Zhejiang Provincial People's HospitalOTHER | 1 | Aug 20, 2025 | clinicaltrials |
| NCT07131501 | A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma | not yet recruiting | Phase 2 | 48 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 20, 2025 | clinicaltrials |
| NCT07128693 | A Single-center, Multicohort, Phase II Clinical Study Evaluating the Combination Therapy of Sacituzumab Tirumotecan in Patients With Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 60 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 0 | Aug 19, 2025 | clinicaltrials |
| NCT06082167 | Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma(STELLAR-305) | active not recruiting | Phase 2 / Phase 3 | 600 | ExelixisINDUSTRY | 26 | Aug 17, 2025 | clinicaltrials |
| NCT07100392 | Tauroursodeoxycholic Acid (TUDCA) Plus Camrelizumab and Regorafenib in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab(LEAF-02) | recruiting | Phase 2 | 141 | Fudan UniversityOTHER | 1 | Aug 17, 2025 | clinicaltrials |
| NCT07105748 | HAIC Combined With Camrelizumab Plus Rivoceranib for Advanced Mixed Hepatocellular-cholangiocarcinoma (HCC-CCA)(TASK-05) | recruiting | Phase 2 | 45 | Fudan UniversityOTHER | 1 | Aug 17, 2025 | clinicaltrials |
| NCT07128251 | A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC) | not yet recruiting | Phase 2 | 47 | Anhui Provincial HospitalOTHER_GOV | 0 | Aug 17, 2025 | clinicaltrials |
| NCT05385861 | Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NET | enrolling by invitation | Phase 1 / Phase 2 | 52 | National Health Research Institutes, TaiwanOTHER | 1 | Aug 15, 2025 | clinicaltrials |
| NCT05822752 | Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)(LIVIGNO-1) | active not recruiting | Phase 2 | 130 | AbbVieINDUSTRY | 7 | Aug 14, 2025 | clinicaltrials |
| NCT07123545 | Autologous Neoantigen-Specific T-Cell Therapy for Advanced Hepatocellular Carcinoma | recruiting | Phase 1 / Phase 2 | 20 | Zhejiang UniversityOTHER | 1 | Aug 14, 2025 | clinicaltrials |
| NCT07116824 | HB1801 Combined Treatment of HER2-positive Breast Cancer | not yet recruiting | Phase 2 | 80 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | Aug 12, 2025 | clinicaltrials |
| NCT07117851 | A Study of Disitamab Vedotin + Bicalutamide in HER2/AR-Positive Scrotal Paget's Disease | recruiting | Phase 2 | 20 | Fudan UniversityOTHER | 1 | Aug 12, 2025 | clinicaltrials |
| NCT03740893 | PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer(PHOENIX) | recruiting | Phase 2 | 119 | Institute of Cancer Research, United KingdomOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT05057013 | A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours | active not recruiting | Phase 1 / Phase 2 | 81 | Cancer Research UKOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT06715592 | ECT STUDY High-grade or Initially Invasive Vulva - GinOnc-ECT Study | active not recruiting | Phase 2 | 18 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT07101900 | 68Ga-NYM096 PET/ CT for the Detection of Clear Cell Renal Cell Carcinoma in Presurgical Patients With Renal Masses | enrolling by invitation | Phase 2 | 100 | Peking Union Medical College HospitalOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT07112833 | A Phase II Clinical Study of Induction Adebrelimab Combined With Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) | not yet recruiting | Phase 2 | 36 | Hebei Medical University Fourth HospitalOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT05002127 | A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06) | active not recruiting | Phase 2 / Phase 3 | 127 | ALX Oncology Inc.INDUSTRY | 12 | Aug 7, 2025 | clinicaltrials |
| NCT06095141 | Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency(PTCA199-6) | recruiting | Phase 2 / Phase 3 | 30 | Fudan UniversityOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT06149689 | mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer(PTCA199-7) | recruiting | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT07101679 | A Study of GnP RegimenCombined With Serplulimab and Stereotactic Body Radiation Therapy as First-line Treatment for Locally Advanced Pancreatic Cancer | recruiting | Phase 2 | 23 | West China HospitalOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT07108309 | BCD-236 in Combination With Chemotherapy in Patients With Relapsed and/or Metastatic Triple Negative Breast Cancer(AREAL) | recruiting | Phase 2 | 124 | BiocadINDUSTRY | 2 | Aug 7, 2025 | clinicaltrials |
| NCT07109401 | Perioperative Immunotherapy for Resectable Limited-Stage SCLC | recruiting | Phase 2 | 37 | Fudan UniversityOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT05690048 | Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA)(FLORA) | recruiting | Phase 2 | 48 | Michael DillOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT07105592 | A Study of Nimotuzumab Plus Adebrelimab With Chemotherapy in Cisplatin-Ineligible Patients With Head And Neck Squamous Cell Carcinoma | recruiting | Phase 1 / Phase 2 | 68 | Fudan UniversityOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT07106528 | Organoid-guided vs Topotecan Therapy in Relapsed Extensive-Stage Small Cell Lung Cancer | not yet recruiting | Phase 2 / Phase 3 | 128 | Peking Union Medical College HospitalOTHER | 0 | Aug 6, 2025 | clinicaltrials |
| NCT06551272 | Microbiota Modification for Immuno-oncology in Hepatocellular Carcinoma(MOTHER) | recruiting | Phase 2 | 34 | Center Eugene MarquisOTHER | 1 | Aug 5, 2025 | clinicaltrials |
| NCT06973525 | This Study Aims to Optimize Neoadjuvant Therapy for HER2-positive Breast Cancer by Implementing a Dynamic Monitoring-guided Treatment Strategy.(HER2-DM-NACT) | not yet recruiting | Phase 2 | 30 | Hebei Medical University Fourth HospitalOTHER | 0 | Aug 5, 2025 | clinicaltrials |
| NCT07103408 | A Study Evaluating Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade for Limited-stage Small Cell Lung Cancer | not yet recruiting | Phase 2 | 56 | Sun Yat-sen UniversityOTHER | 1 | Aug 5, 2025 | clinicaltrials |
| NCT07104266 | Triple Negative Breast Cancer and Celecoxib. Pilot Study | recruiting | Phase 2 | 30 | Université de SherbrookeOTHER | 1 | Aug 5, 2025 | clinicaltrials |
| NCT04675333 | Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04) | active not recruiting | Phase 2 | 172 | ALX Oncology Inc.INDUSTRY | 8 | Aug 3, 2025 | clinicaltrials |
| NCT04675294 | Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03) | active not recruiting | Phase 2 | 189 | ALX Oncology Inc.INDUSTRY | 9 | Aug 1, 2025 | clinicaltrials |
| NCT07097935 | Study of HS-10516 Combination Therapy in Patients With Advanced Renal Cell Carcinoma | recruiting | Phase 1 / Phase 2 | 104 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 1, 2025 | clinicaltrials |
| NCT07097948 | Toripalimab Combined With Chemotherapy as Adjuvant Therapy for Incidental Small Cell Lung Cancer After Radical Resection of Lung Cancer: A Single-Center, Randomized Controlled Clinical Study Protocol Number: LungMate-033(Adjuvant) | not yet recruiting | Phase 2 | 40 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Aug 1, 2025 | clinicaltrials |
| NCT07097064 | Evaluation of the Stereotactic MR-guided Adaptive Radiotherapy for Locally Advanced Pancreatic Cancers(RAIPANC) | not yet recruiting | Phase 2 | 160 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Jul 31, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Aug 27, 2025source: clinicaltrials